This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
October 14, 2020
GenSight Biologics Appoints Elsy Boglioli to its Board of Directors
October 14, 2020
Targovax ASA – successfully completed private placement
October 14, 2020
Spruce Biosciences Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 14, 2020
Oncopeptides signs € 40 million loan agreement with the EIB
October 13, 2020
Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer
October 12, 2020
Priothera closes €30 million Series A financing to develop highly promising therapies for acute myeloid leukemia (AML)
October 12, 2020
With the priority review underway at FDA, Oncopeptides moves forward with intent to file for conditional approval of melflufen with EMA
October 12, 2020
Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors
October 09, 2020
Spruce Biosciences Announces Pricing of Upsized Initial Public Offering
October 08, 2020
Nordic Nanovector publishes results of preclinical study demonstrating Betalutin® reverses tumour resistance to rituximab in NHL disease models